Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by forhandlarenon Oct 17, 2022 1:32pm
137 Views
Post# 35029394

RE:Responsibility Howard Verrico

RE:Responsibility Howard VerricoI have a rather substantial investment so I really need the company to be successful.

That said, I think some critisism and doubts is inevitable as the situation has unfolded.

Honestly - I don't know if management even care about the share price. The deal with Abbvie reflects their great plan - and that is an exit - not today, not tomorrow but maybe in 5 years?

Howard is not a businessman even if the almighty MD certainly believe that.

This long term revenue will be a long wait to materialize. The marketing contradicts this in multiple aspects where the investors are led to believe that action and revenue is just around the corner.

For example the institutional investors - we might think that Howard is about to meet with them, and maybe he will eventually, but before he can presents any meaningful numbers there's no point. They will for sure see behind his inflated market share numbers that he try to sell us.

Being humble, honest and transparent isn't Howards style. Better underperform than overdeliver on expectations he builds!

The current share price is the markets way to say, enough is enough!

My fear is that they will continue to structure every deal in the same way. Minimal up-front to maximize royalty.

I would combine long term with short term in order to gain investors confidence. So the pet diabetes deal should have a substantial up-front since I realize that's really needed to keep at least some investors.
<< Previous
Bullboard Posts
Next >>